Reactions Following Completion of 1 and 2 Year Multidrug Therapy (MDT)

被引:36
作者
Balagon, Ma Victoria F. [2 ]
Gelber, Robert H. [1 ]
Abalos, Rodolfo M. [2 ]
Ceilona, Roland V. [2 ]
机构
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[2] Leonard Wood Mem Ctr Leprosy Res, Epidemiol Branch, Cebu, Philippines
关键词
MULTIBACILLARY LEPROSY PATIENTS; REVERSAL REACTIONS; TYPE-1; REACTIONS; SKIN-LESIONS; EXPRESSION; EXPERIENCE; MANAGEMENT; NEURITIS; RELAPSE;
D O I
10.4269/ajtmh.2010.09-0586
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
We evaluated the incidence. severity, and duration of reactional states in 139 multibacillary (MB) leprosy patients in the first 2 years after the completion of the 1 year regimen of multidrug therapy (MDT) currently recommended by the World Health Organization (WHO) and compared those findings with 295 MB leprosy patients treated with the same regimen previously recommended for 2 years During the first year after the completion of 1 year MDT, patients experienced 1 or more reactional states 27% of the time, the vast majority being lepra type 1 reactions (reversal reactions. RR). whereas patients who received 2 year MDT experienced a reactional state during that time per kid only 8% of the time (P < 0 001) Furthermore, during the first year after the completion of therapy. and during the first 2 years. both the number of reactional states and reversal reactions were significantly (P <= 0 004) mole frequent. severe. of longer duration. and more commonly associated with neuritis.
引用
收藏
页码:637 / 644
页数:8
相关论文
共 36 条
[1]  
BOERRIGTER G, 1991, INT J LEPROSY, V59, P255
[2]  
Britton WJ, 1998, LEPROSY REV, V69, P225
[3]  
Cellona RV, 2003, INT J LEPROSY, V71, P308, DOI 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO
[4]  
2
[5]   ANALYSIS OF NATURALLY-OCCURRING DELAYED-TYPE HYPERSENSITIVITY REACTIONS IN LEPROSY BY INSITU HYBRIDIZATION [J].
COOPER, CL ;
MUELLER, C ;
SINCHAISRI, TA ;
PIRMEZ, C ;
CHAN, J ;
KAPLAN, G ;
YOUNG, SMM ;
WEISSMAN, IL ;
BLOOM, BR ;
REA, TH ;
MODLIN, RL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (05) :1565-1581
[6]  
DERIJK AJ, 1994, LEPROSY REV, V65, P320
[7]  
Gelber RH, 2004, INT J LEPROSY, V72, P493, DOI 10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO
[8]  
2
[9]  
Girdhar BK, 2000, LEPROSY REV, V71, P144
[10]  
JAMET P, 1995, INT J LEPROSY, V63, P195